Suprane
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Suprane
Suprane Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Suprane (desflurane, USP) Volatile Liquid for Inhalation is an anesthetic used in surgery. Common side effects of Suprane include headache, nausea, dizziness, and vomiting.
Talk to your doctor about your individual dosage recommendation. Suprane must be administered under a doctor's supervision. Benzodiazepines, opioids, neuromuscular blocking agents, and muscle relaxers may interact with Suprane. Tell your doctor all medications you take. Do not drive, use machinery, or do any activity that requires alertness when taking Suprane. If you are pregnant only use Suprane if clearly needed. Exercise caution if you take Suprane while breastfeeding.
Our Suprane (desflurane, USP) Volatile Liquid for Inhalation Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Suprane FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
Clinical Trials Experience
Adverse event information is derived from controlled clinical trials, the majority of which were conducted in the United States. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length. Most adverse events reported were mild and transient, and may reflect the surgical procedures, patient characteristics (including disease) and/or medications administered.
Of the 2,143 patients exposed to SUPRANE (desflurane) in clinical trials, 370 adults and 152 children were induced with SUPRANE (desflurane) alone and 987 patients were maintained principally with SUPRANE (desflurane) . The frequencies given reflect the percent of patients with the event. Each patient was counted once for each type of adverse event. They are presented in alphabetical order according to body system.
Table 2: Frequency of Events Occurring in Greater Than 1%
of Clinical Trial Patients (in Reports Deemed "Probably Causally Related")
| Induction (use as a mask inhalation agent) | |
| Adult Patients (N=370) : | Coughing 34%, breathholding 30%, apnea 15%,increased secretions*, laryngospasm*, oxyhemoglobin desaturation (SpO2 < 90%)*, pharyngitis*. |
| Maintenance or Recovery Adult and Intubated Pediatric Patients (N=687): | |
| Body as a Whole | Headache |
| Cardiovascular | Bradycardia, hypertension, nodal arrhythmia, tachycardia |
| Digestive | Nausea 27%, vomiting 16% |
| Nervous system | Increased salivation |
| Respiratory | Apnea*, breathholding, cough increased*, laryngospasm*, pharyngitis |
| Special Senses | Conjunctivitis (conjunctival hyperemia) |
| *Incidence of events 3% - 10% | |
Frequency of Events Occurring in Less Than 1% of Patient (in Reports Deemed "Probably Causally Related")
Reported in 3 or more patients, regardless of severity
Adverse reactions reported only from postmarketing experience or in the literature, not seen in clinical trials, are considered rare and are italicized.
| Cardiovascular | Arrhythmia, bigeminy, abnormal electrocardiogram, myocardial ischemia, vasodilation |
| Digestive | Hepatitis |
| Nervous System | Agitation, dizziness |
| Respiratory | Asthma, dyspnea, hypoxia |
Frequency of Events Occurring in Less Than 1% of Clinical Trial Patients (in Reports Deemed "Causal Relationship Unknown")
Reported in 3 or more patients, regardless of severity
| Body as a Whole | Fever |
| Cardiovascular | Hemorrhage, myocardial infarct |
| Metabolic and Nutrition | Increased creatinine phosphokinase |
| Musculoskeletal System | Myalgia |
| Skin and Appendages | Pruritus |
Post Marketing Experience
The following adverse reactions have been identified during post-approval use of SUPRANE (desflurane) . Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders: Coagulopathy
Metabolism and Nutrition Disorders: Hyperkalemia, Hypokalemia, metabolic acidosis
Nervous System Disorders: Convulsion
Eye Disorders: Ocular icterus
Cardiac Disorders: Cardiac arrest, Torsade de pointes, ventricular failure, ventricular hypokinesia
Vascular Disorders: Malignant hypertension, hemorrhage, hypotension, shock
Respiratory, Thoracic and Mediastinal Disorders: Respiratory arrest, respiratory failure, respiratory distress, bronchospasm, hemoptysis
Gastrointestinal Disorders: Pancreatitis acute, abdominal pain
Hepatobiliary Disorders: Hepatic failure, hepatic necrosis, cytolytic hepatitis, cholestasis, jaundice, hepatic function abnormal, liver disorder
Skin and Subcutaneous Tissue Disorder: Urticaria, erythema,
Musculoskeletal, Connective Tissue and Bone Disorders: Rhabdomyolysis
General Disorders and Administration Site Conditions: Hyperthermia malignant, asthenia, malaise
Investigations: Electrocardiogram ST-T change, electrocardiogram T-wave inversion, tranaminases increased, alanine aminotransferase increased, aspartate aminotransferase increased, coagulation test abnormal, ammonia increased
Injury, Poisoning, and Procedural Complications*: Tachyarrhythmia, palpitations, eye burns, blindness transient, encephalopathy, ulcerative keratitis, ocular hyperemia, visual acuity reduced, eye irritation, eye pain, dizziness, migraine, fatigue, accidental exposure, skin burning sensation, drug administration error
*All of reactions categorized within this SOC were accidental exposures to non-patients.
Read the entire FDA prescribing information for Suprane (Desflurane) »
Additional Suprane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
